Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Borgo C, D'Amore C, Sarno S, Salvi M, Ruzzene M. · 2021

Read Protein kinase CK2: a potential therapeutic target for diverse human diseases. by Borgo C, D'Amore C, Sarno S, Salvi M, Ruzzene M. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8126563.txt.

Description

Borgo and co-authors make the case for protein kinase CK2 as a drug target across many diseases. CK2 is always on, unlike most signaling enzymes. It tags hundreds of proteins with phosphate groups. In cancer it touches nearly every malignant hallmark known. Viruses also lean on it to complete their life cycles. SARS-CoV-2 even boosts CK2 activity inside infected cells.

The target list keeps growing beyond oncology. Brain diseases, inflammation, and autoimmune disorders all implicate CK2. Eye diseases, diabetes, and obesity join the roster. Heart injury, vessel disease, and cystic fibrosis appear too. Mutations in CK2 itself cause psychiatric and developmental syndromes. Potent, specific inhibitors of the enzyme already exist. That rare readiness strengthens the pharmacological case. The review weighs each disease claim against fresh evidence. One always-on kinase may serve many clinics.

Catalog record

CREATORBorgo C, D'Amore C, Sarno S, Salvi M, Ruzzene M.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE144 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8126563

Browse the full library · About the Tower of Babel